Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques

Vidyleison Neves Camargos; Shannan L. Rossi; Terry L. Juelich; Jennifer K. Smith; Nikos Vasilakis; Alexander N. Freiberg; Richard Nichols; Joan Fusco

doi:10.3390/v16081181

July 24, 2024VirusesOpen Access

Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques

View Full Paper

Ask AI

Bookmark

Share

Key Points

A single dose of recombinant vesicular stomatitis virus vaccine provides protective efficacy against lethal filoviruses including Marburg virus in nonhuman primates.
Evaluation in the lethal cynomolgus macaque model tested single-dose vaccination with rVSV-MARV across low viral titers to assess protection against fatal infection.
Immunogenicity findings support rVSV-MARV development to prevent Marburg hemorrhagic fever; cynomolgus macaque model limits mandate further clinical evaluation in humans.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Preclinical evaluation demonstrates protective efficacy of an rVSV-MARV vaccine in cynomolgus macaques, suggesting a viable countermeasure against fatal Marburg virus infection.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Camargos et al. (2024) studied this question.

synapsesocial.com/papers/68e5f3e3b6db643587587e1a https://doi.org/10.3390/v16081181

View Full Paper

Ask AI

Bookmark

Share

Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading